Odyssey Therapeutics (ODTX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.02

Estimate

-$0.93

Surprise

-9.9%

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Odyssey Therapeutics (ODTX) reported a wider loss than forecast — adjusted EPS of -$1.02 against the -$0.93 estimate (a 9.9% shortfall).

• Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update — fiscal.ai, 2026-11-04
• Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate — benzinga, 2026-11-04

TrendMatrix currently rates ODTX Sell at 5.3/10; no pre/post engine snapshot brackets this report.

0 of the last 3 quarters beat the estimate; this quarter's -9.9% surprise compares with a -162.0% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$19.50

Price target

$30.74

Stop

$18.14

Upside to target

+57.6%

Reward-to-risk

3.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$937.1M

P/E (fwd)

-4.5

52-week range

$15.10–$29.05

Off 52-week high

32.9%

RSI (14)

62

Volume vs avg

2.48×

Score today

5.3/10